A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors

This study is testing a new oral medication called NST-628 for adults with advanced solid tumor cancers. It aims to see if this drug is safe and effective for people whose cancer depends on specific genetic pathways to grow and who have already tried standard treatments.

You may be eligible if you are at least 18 years old and have an advanced solid tumor—such as lung cancer, melanoma, or brain tumors—with specific genetic changes. This study is designed for patients who have found that standard cancer treatments are no longer working or are not a good fit.

Participants will take the experimental medication, NST-628, in tablet form. The research team will closely monitor your health to see how your body reacts to the medicine and to track how the tumor responds to the treatment.

This study is currently recruiting patients at medical centers in San Francisco and Los Angeles, California, as well as Denver, Colorado. You can talk to your doctor to see if these locations are accessible for you.